Quick Answer
Structure Therapeutics Inc. reported R&D Expense of $225.25 million for fiscal year 2025.
Structure Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $225.25M | +107.0% |
| 2024 | $108.81M | +55.2% |
| 2023 | $70.10M | +93.7% |
| 2022 | $36.19M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $58.99M | +81.0% | +7.8% |
| June 30, 2025 | $54.71M | +148.1% | +27.6% |
| March 31, 2025 | $42.87M | +107.3% | +31.5% |
| September 30, 2024 | $32.60M | +86.1% | +47.8% |
| June 30, 2024 | $22.05M | +13.6% | +6.6% |
| March 31, 2024 | $20.68M | +57.4% | +18.1% |
| September 30, 2023 | $17.52M | +91.2% | -9.8% |
| June 30, 2023 | $19.41M | +90.7% | +47.8% |
- Structure Therapeutics Inc. showed an increase of +107.0% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Structure Therapeutics Inc.’s r&d expense has grown by 522.4% (from $36.19 million to $225.25 million).
- The most recent figure is from Structure Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: